Scarica l'app Stockscreener
8.65
5.46%
-0.50
Pre-mercato:
8.65
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VIR Giù?
Forum
Previsione
Precedente Chiudi:
$9.15
Aprire:
$9.09
Volume 24 ore:
1.33M
Relative Volume:
0.67
Capitalizzazione di mercato:
$1.46B
Reddito:
$68.56M
Utile/perdita netta:
$-437.99M
Rapporto P/E:
-2.734
EPS:
-3.1639
Flusso di cassa netto:
$-396.61M
1 W Prestazione:
-9.33%
1M Prestazione:
-13.59%
6M Prestazione:
+33.08%
1 anno Prestazione:
+67.96%
Intervallo 1D:
$8.63
$9.19
Intervallo di 1 settimana:
$8.63
$9.49
Portata 52W:
$4.155
$11.66
Vir Biotechnology Inc Stock (VIR) Company Profile
Nome
Vir Biotechnology Inc
Settore
Industria
Telefono
415-906-4324
Indirizzo
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
8.65 | 1.54B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | Iniziato | Evercore ISI | Outperform |
| 2025-08-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-03-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Iniziato | SVB Leerink | Outperform |
| 2022-09-09 | Iniziato | Morgan Stanley | Underweight |
| 2022-03-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-01-27 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-09-14 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-11 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Iniziato | Needham | Buy |
| 2020-03-19 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2020-02-27 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Iniziato | Robert W. Baird | Neutral |
| 2019-11-05 | Iniziato | Barclays | Overweight |
| 2019-11-05 | Iniziato | Cowen | Outperform |
| 2019-11-05 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Vir Biotechnology Inc Borsa (VIR) Ultime notizie
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now? - Insider Monkey
Earnings call transcript: Vir Biotech reports larger-than-expected Q1 2026 loss - Investing.com
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership - Stocktwits
Vir Biotech Q1 2026 presentation: $2.2B partnerships fuel oncology pivot - Investing.com
VIR Maintained by Leerink Partners -- Price Target Raised to $21 - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $21.00 - MarketBeat
Insider Sell: Brent Sabatini Sells Shares of Vir Biotechnology I - GuruFocus
Vir Biotechnology director Janet Napolitano sells $30,239 in stock By Investing.com - Investing.com India
Vir Biotechnology director Janet Napolitano sells $30,239 in stock - Investing.com
Vir Biotechnology (VIR) director Napolitano sells 3,200 shares under 10b5-1 plan - Stock Titan
Vir Biotechnology (VIR) SVP sells 379 shares in pre-planned trade - Stock Titan
VIR (NASDAQ: VIR) Form 144 lists 379 ESPP shares; insider sold 7,711 - Stock Titan
[144] Vir Biotechnology, Inc. SEC Filing - Stock Titan
Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Vir Biotechnology, Inc. (VIR) Presents at EASL Congress 2026Slideshow (NASDAQ:VIR) 2026-05-30 - Seeking Alpha
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million - AOL.com
Vir Biotechnology (VIR) director receives RSU and stock option grants - Stock Titan
Vir Biotechnology (VIR) director granted 8,000 RSUs and 16,000 options - Stock Titan
Vir Biotechnology (VIR) director granted RSUs and 16,000-share stock option - Stock Titan
Vir Biotechnology (VIR) director receives 8,000 RSUs and 16,000 stock options - Stock Titan
Vir Biotechnology (VIR) director awarded 8,000 RSUs and 16,000-share stock option - Stock Titan
Vir Biotechnology (VIR) director granted RSUs and 16,000-share option - Stock Titan
Vir Biotechnology, Inc. 8-K Filing Details for May 25, 2026: Company Information, NASDAQ Listing, and Executive Certification - Minichart
Vir Biotechnology, Inc. Announces Changes in Board and Audit Committee, Effective May 26, 2026 - marketscreener.com
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), GeoVax Labs (GOVX) and Vir Biotechnology (VIR) - The Globe and Mail
Vir Biotechnology (Nasdaq: VIR) reports director exit and 2026 vote outcomes - Stock Titan
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally - AOL.com
UBS Group AG Purchases 203,203 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
Gilead wins hepatitis D drug approval as two Bay Area rivals line up their drugs - The Business Journals
How Marianne De Backer saved Vir after flu drug failure - The Business Journals
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares - AOL.com
How SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment Story - Yahoo Finance
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally - The Motley Fool
Vir Biotechnology’s SWOT analysis: stock gains momentum on partnership and clinical progress - Investing.com UK
Earnings call transcript: Vir Biotech’s Q1 2026 sees wider losses, stock dips - Investing.com Nigeria
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver Congress 2026 - marketscreener.com
VIR: Vir Biotechnology Prepares to Present Trial Data at EASL Co - GuruFocus
Vir Biotechnology to present hepatitis delta trial data at EASL By Investing.com - Investing.com South Africa
Vir Biotechnology to present hepatitis delta trial data at EASL - Investing.com UK
Vir Biotechnology Inc Azioni (VIR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vir Biotechnology Inc Azioni (VIR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sabatini Brent | SVP, Chief Accounting Officer |
Jun 01 '26 |
Sale |
9.45 |
379 |
3,582 |
61,902 |
1.13%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):